Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

Journal of Bone and Mineral Research

Volumn 21, Issue 7, 2006, Pages 1113-1120

  Seeman, Ego ^a,m   Vellas, Bruno ^b   Benhamou, Claude ^c   Aquino, Jean Pierre ^d   Semler, Jutta ^e   Kaufman, Jean Marc ^f   Hoszowski, Krzysztof ^g   Varela, Alfredo Roces ^h   Fiore, Carmelo ⁱ   Brixen, Kim ^j   Reginster, Jean Yves ^k   Boonen, Steven ^l  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHU PURPAN   (France)

^c Hôpital Porte Madeleine   (France)

^d Service de médecine physique et de réadaptation   (France)

^e MARTIN LUTHER KRANKENHAUS   (Germany)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Centrum Medyczcne   (Poland)

^h HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

ⁱ UNIVERSITY OF CATANIA   (Italy)

^j ODENSE UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m AUSTIN HEALTH   (Australia)

more..

Author keywords

Strontium ranelate; Vertebral and nonvertebral fractures risk reduction; Women >80 years of age

Indexed keywords

PLACEBO; STRONTIUM RANELATE;

AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITOMETRY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OSTEOARTHROPATHY; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; VERTEBRA FRACTURE;

EID: 33745494818     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060404     Document Type: Article

References (30)

1. Population Division of the Department of Economic and Social Affairs of the Nations Secretariat 2002 World Population Prospects: The 2002 Revision and World Urban Prospects. Available online at http://esa.un.org/unpp. Accessed January 2006.
2. Ettinger MP 2003 Aging bone and osteoporosis: Strategies for preventing fractures in the elderly. Arch Intern Med 163:2237-2246.
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R. Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
6. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
7. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML. Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
8. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention program Study Group. N Engl J Med 344:333-340.
9. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832-1839.
10. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ 2006 Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (in press).
11. Marie PJ, Amman P, Boivin G, Rey C 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121-129.
12. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468.
13. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: TReatment Of Peripheral OSsteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90:2816-2822.
14. Committee for Proprietary Medicinal Products 2001 Note for Guidance on Post Menopausal Osteoporosis in Women Rev. 1 (CPMP adopted January 2001). European Agency for Evaluation of Medicinal Products, London, UK.
15. Food and Drug Adminstration 1994 Draft Guidance Postmenopausal Osteoporosis. Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD, USA.
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148.
17. Reginster JY, Janssen C, Deroisy R, Zegels B, Albert A, Franchimont P 1995 Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: Normal range and fracture threshold for western European (Belgian) postmenopausal females. Clin Rheumatol 14:68-75.
18. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R 1998 Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489.
19. Slosman DO, Provvedini DM, Meunier PJ, Delmas P, Sebert JL, De Vernejoul MC, Tsouderos Y, Reginster JY 1999 The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 2:37-44.
20. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA 2004 Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34:195-202.
21. Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E 2006 Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone (in press).
22. Chrischilles E, Shireman T, Wallace R 1994 Costs and health effects of osteoporotic fractures. Bone 15:377-386.
23. Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S 2000 Costs induced by hip fractures: A prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373-380.
24. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III 1993 Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005.
25. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P, Tsouderos Y, Delmas PD, Christiansen C 2001 Incorporation and distribution of strontium in bone. Bone 28:446-453.
26. Nielsen SP, Slosman D, Sorensen OH, Basse-Cathalinat B, De Cassin P, Roux CR, Meunier PJ 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 2:371-379.
27. Reginster JY, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Lorenc R, Pors-Nielsen S, De-Vernejoul MC, Roces A, Meunier PJ 2001 Strontium ranelate: Dose-dependent effects in postmenopausal osteoporosis: The STRATOS 2-year randomised trial. Clin Rheumatol 20:OP22.
28. Slosman DO, Rizzoli R, Pichard C, Donath A, Bonjour JP 1994 Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int 4:185-190.
29. Briancon D, de Gaudemar JB, Forestier R 2004 Management of osteoporosis in women with peripheral osteoporotic fractures after 50 years of age: A study of practices. Joint Bone Spine 71:128-130.
30. Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M 2003 Older women with fractures: Patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 85:2294-2302.